Agree wholehearted with you Falconer. The digram of our drugs and planned clinical trials has a orange bordered arrow indicating a P2/3 for Fragile X, thus is consequently in the planning phase. Our former FDA managers may be working a trial architecture with the FDA that will enable "Blanket Trial" expansion into other autism spectrum diseases. This is especially true of those which have uncontrollable body movements/spasms (like Rett, Frail X, Infantile Spasms, and Angelman's).